Klinická farmakologie a farmacie – 2/2021

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2021; 35(1): 94–98 / www.klinickafarmakologie.cz 98 PŘEHLEDOVÉ ČLÁNKY Metamizol (dipyron) 23. Lutz M. Metamizole (Dipyrone) and the Liver: A Review of the Literature. J Clin Pharmacol. 2019; 59(11): 1433–1442. doi: 10.1002/jcph.1512. 24. Rogosch T, Sinning C, Podlewski A et al. Novel bioactive metabolites of dipyrone (metamizol). Bioorg Med Chem. 2012; 20(1): 101–107. doi: 10.1016/j.bmc.2011.11.028. 25. Nikolova I, Tencheva J, Voinikov J et al. Metamizole: A Re- view Profile of a Well-Known „Forgotten“ Drug. Part I: Phar- maceutical and Nonclinical Profile. Biotechnology & Biotech- nological Equipment. 2012; 26(6): 3329–3337. doi: 10.5504/ BBEQ.2012.0089. 26. Zylber-Katz E, Granit L, Levy M. Plasma protein binding of dipyrone metabolites in man. Eur J Clin Pharmacol. 1985; 29(1): 67–71. doi: 10.1007/BF00547371. 27. Vlahov V, Badian M, Verho M, Bacracheva N. Pharmacoki- netics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium. Eur J Clin Pharma- col. 1990; 38(1): 61–65. doi: 10.1007/BF00314805. 28. Zylber-Katz E, Granit L, Levy M. Formation and excretion of dipyrone metabolites in man. Eur J Clin Pharmacol. 1992; 42(2): 187–191. doi: 10.1007/BF00278482. 29. Heinemeyer G, Gramm HJ, Roots I, Dennhardt R, Simgen W. The kinetics of metamizol and its metabolites in critical- -care patients with acute renal dysfunction. Eur J Clin Phar- macol. 1993; 45(5): 445–450. doi: 10.1007/BF00315516. 30. Zylber-Katz E, Granit L, Stessman J et al. Effect of age on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol. 1989; 36(5): 513–516. doi: 10.1007/BF00558078. 31. Zylber-Katz E, Caraco Y, Granit L, Levy M. Dipyrone meta- bolism in liver disease. Clin Pharmacol Ther. 1995; 58(2): 198– 209. doi: 10.1016/0009-9236(95)90198-1. 32. Saussele T, Burk O, Blievernicht JK et al. Selective indu- ction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther. 2007; 82(3): 265–274. doi: 10.1038/sj.clpt.6100138. Epub 2007 Mar 7. 33. Doña I, Blanca-López N, Cornejo-García JA et al. Charac- teristics of subjects experiencing hypersensitivity to nonste- roidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011; 41(1): 86–95. doi: 10.1111/j.1365-2222.2010.03651.x 34. Nissen CV, Bindslev-Jensen C, Mortz CG. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs): classifi- cation of a Danish patient cohort according to EAACI/ENDA guidelines. Clin Transl Allergy. 2015; 5: 10. Published 2015 Mar 3. doi: 10.1186/s13601-015-0052-0. 35. Ortega N, Doña I, Moreno E et al. Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti- -inflammatory drugs. J Investig Allergol Clin Immunol. 2014; 24(5): 308–323. 36. Kowalski ML, Asero R, Bavbek S et al. Classification and practical approach to the diagnosis and management of hy- persensitivity to nonsteroidal anti-inflammatory drugs. Aller- gy. 2013; 68(10): 1219–1232. doi: 10.1111/all.12260. 37. Prados M, Labella M, Baynova K. Accelerated-type Re- actions to High Parenteral Doses of Metamizole in Patients Who Tolerated Therapeutic Doses of Oral Metamizole and Other NSAIDs. J Investig Allergol Clin Immunol. 2016; 26(6): 378–379. doi: 10.18176/jiaci.0098. 38. Rebelo Gomes E, Geraldes L, Gaspar  et al. Hypersen- sitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs among Adults: Clinical Features and Risk Factors for Diagno- sis Confirmation. Int Arch Allergy Immunol. 2016; 171(3–4): 269–275. doi: 10.1159/000452627. 39. Levy M. Hypersensitivity to pyrazolones. Thorax. 2000; 55 Suppl 2(Suppl 2): S72–S74. doi: 10.1136/thorax.55.suppl_2.s72 40. Bellegrandi S, Rosso R, Mattiacci G et al. Combined imme- diate- and delayed-type hypersensitivity to metamizole. Aller- gy. 1999; 54(1): 88–90. doi: 10.1034/j.1398-9995.1999.00953.x 41. Quiralte J, Delgado J, Sáenz de San Pedro B et al. Safety of the new selective cyclooxygenase type 2 inhibitors rofe- coxib and celecoxib in patients with anaphylactoid reacti- ons to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2004; 93(4): 360–364. doi: 10.1016/s1081- 1206(10)61395-6. 42. CHMP Assessment report [online]. European Medicines Agency, 2018 [cit. 2021-01-01]. Dostupné z: https: //www.ema. europa.eu/en/documents/referral/metamizole-article-31-re- ferral-chmp-assessment-report_en.pdf. 43. Metamizol – dávkování, použití v těhotenství a během ko- jení [online]. SÚKL, 2018 [cit. 2021-01-01]. Dostupné z: https: //www.sukl.cz/metamizol-davkovani-pouziti-v-tehotenst- vi-a-behem-kojeni. 44. Informační dopis – Metamizol: Riziko léky indukovaného poškození jater [online]. SÚKL, 2020 [cit. 2021-01-01]. Dostup- né z: https: //www.sukl.cz/file/94704_1_1.